BioSpace News Archive

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, reported financial and operating results for the second quarter ended June 30, 2021.

Landos Biopharma, Inc., a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.

Antares Pharma, Inc., a specialty pharmaceutical company, reported financial and operating results for the second quarter ended June 30, 2021 with record revenue of $45.0 million and net income of $4.4 million, or $0.03 per basic and diluted earnings per share.

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended June 30, 2021 on Thursday, August 12, 2021.

Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced recent corporate updates and financial results for the second quarter ended June 30, 2021.

Kamada Ltd., a plasma-derived biopharmaceutical company, announced that it will release financial results for the three and six months ended June 30, 2021, prior to the open of the U.S. financial markets on Wednesday, August 11, 2021.

Kala Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the quarter ended June 30, 2021.